Lifecore Biomedical, Inc. (LFCR)

Lifecore Biomedical Cash Flow Statement

Financials in millions USD. Fiscal year is June - May.

Year Ending	TTM	May 28, 2023	May 29, 2022	May 30, 2021	May 31, 2020	May 26, 2019
Net Income	-99.56	-99.56	-116.72	-32.29	-38.19	0.41
Depreciation & Amortization	13.29	13.29	18.06	19.87	18.84	15.23
Share-Based Compensation	3.61	3.61	2.61	3.36	2.42	3.56
Other Operating Activities	65.23	65.23	73.45	25.54	-0.11	-3.18
Operating Cash Flow	-17.44	-17.44	-22.59	16.47	-17.04	16.02
Operating Cash Flow Growth	-	-	-	-	-	-19.01%
Capital Expenditures	-21.48	-21.48	-28.8	-12.31	-24.25	-44.47
Acquisitions	16.67	16.67	63.66	0	0	-59.87
Change in Investments	0	0	45.1	0	0.36	7.55
Investing Cash Flow	-4.81	-4.81	79.96	-12.31	-23.89	-96.8
Share Issuance / Repurchase	4.82	4.82	0	0	0.03	0.33
Debt Issued / Paid	-2.93	-2.93	-56.23	-3.01	40.2	79.4
Other Financing Activities	37.81	37.81	-0.79	-0.41	-0.21	-0.7
Financing Cash Flow	39.7	39.7	-57.02	-3.42	40.02	79.03
Net Cash Flow	17.45	17.45	0.35	0.74	-0.91	-1.75
Free Cash Flow	-38.92	-38.92	-51.39	4.16	-41.29	-28.45
Free Cash Flow Margin	-37.69%	-37.69%	-46.19%	4.12%	-25.80%	-5.10%
Free Cash Flow Per Share	-1.30	-1.30	-1.74	0.14	-1.42	-1.00

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).